DK3290035T3 - Procaspase-kombinationsterapi til behandling af cancer - Google Patents

Procaspase-kombinationsterapi til behandling af cancer Download PDF

Info

Publication number
DK3290035T3
DK3290035T3 DK17180400.8T DK17180400T DK3290035T3 DK 3290035 T3 DK3290035 T3 DK 3290035T3 DK 17180400 T DK17180400 T DK 17180400T DK 3290035 T3 DK3290035 T3 DK 3290035T3
Authority
DK
Denmark
Prior art keywords
procaspase
combination therapy
cancer treatment
cancer
treatment
Prior art date
Application number
DK17180400.8T
Other languages
Danish (da)
English (en)
Inventor
Paul J Hergenrother
Rachel C Botham
Timothy M Fan
Mark J Gilbert
Michael K Handley
Avadhut Joshi
Gregory J Riggins
Theodore M Tarasow
Original Assignee
Univ Illinois
Univ Johns Hopkins
Vanquish Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Univ Johns Hopkins, Vanquish Oncology Inc filed Critical Univ Illinois
Application granted granted Critical
Publication of DK3290035T3 publication Critical patent/DK3290035T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK17180400.8T 2012-03-06 2013-03-06 Procaspase-kombinationsterapi til behandling af cancer DK3290035T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607103P 2012-03-06 2012-03-06
EP13758061.9A EP2822546B1 (en) 2012-03-06 2013-03-06 Procaspase combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
DK3290035T3 true DK3290035T3 (da) 2019-08-05

Family

ID=49117298

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17180400.8T DK3290035T3 (da) 2012-03-06 2013-03-06 Procaspase-kombinationsterapi til behandling af cancer
DK13758061.9T DK2822546T3 (en) 2012-03-06 2013-03-06 PROCASPACE COMBINATION THERAPY FOR CANCER TREATMENT

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13758061.9T DK2822546T3 (en) 2012-03-06 2013-03-06 PROCASPACE COMBINATION THERAPY FOR CANCER TREATMENT

Country Status (14)

Country Link
US (5) US9421202B2 (enExample)
EP (2) EP3290035B1 (enExample)
JP (2) JP6222608B2 (enExample)
KR (1) KR102075811B1 (enExample)
CN (1) CN104540501B (enExample)
AU (1) AU2013230985B2 (enExample)
BR (1) BR112014022123B1 (enExample)
CA (1) CA2866020C (enExample)
DK (2) DK3290035T3 (enExample)
ES (2) ES2738448T3 (enExample)
IN (1) IN2014MN01944A (enExample)
MX (1) MX359209B (enExample)
RU (1) RU2636234C2 (enExample)
WO (1) WO2013134398A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
DK3290035T3 (da) 2012-03-06 2019-08-05 Univ Illinois Procaspase-kombinationsterapi til behandling af cancer
JP7033451B2 (ja) * 2015-06-05 2022-03-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ Pac-1併用療法
KR101712638B1 (ko) 2015-08-19 2017-03-07 한국과학기술연구원 Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
CA3082575A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CA3109191A1 (en) 2018-08-09 2020-02-13 The Board Of Trustees Of The University Of Illinois Imidazotetrazine compounds
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
WO2020180581A1 (en) * 2019-03-05 2020-09-10 Dow Global Technologies Llc Inducing caspase activity
CA3142157A1 (en) * 2019-05-30 2020-12-03 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
US6303329B1 (en) 1998-07-27 2001-10-16 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
CN101184491A (zh) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20070049602A1 (en) 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
RU2408584C2 (ru) * 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
WO2007033374A2 (en) * 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US7886969B2 (en) 2005-12-06 2011-02-15 Visa U.S.A. Inc. Method and system for loading and reloading portable consumer devices
CA2651395A1 (en) 2006-05-19 2007-11-29 Board Of Trustees Of The University Of Illinois Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
RU2360692C1 (ru) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
BRPI0907162A2 (pt) 2008-01-11 2015-07-07 Univ California Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
CN106946812B (zh) 2009-02-09 2020-10-09 伊利诺伊大学评议会 作为个性化抗癌药的胱天蛋白酶原活化化合物的设计、合成和评价
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
DK3290035T3 (da) 2012-03-06 2019-08-05 Univ Illinois Procaspase-kombinationsterapi til behandling af cancer

Also Published As

Publication number Publication date
IN2014MN01944A (enExample) 2015-07-10
EP2822546A4 (en) 2015-10-28
US20150025083A1 (en) 2015-01-22
BR112014022123A2 (enExample) 2017-06-20
AU2013230985A1 (en) 2014-10-16
US11844798B2 (en) 2023-12-19
US10085978B2 (en) 2018-10-02
EP3290035B1 (en) 2019-05-15
DK2822546T3 (en) 2017-10-30
EP3290035A1 (en) 2018-03-07
MX2014010714A (es) 2015-03-10
KR102075811B1 (ko) 2020-02-10
CN104540501A (zh) 2015-04-22
AU2013230985B2 (en) 2016-05-12
JP2018052932A (ja) 2018-04-05
US10874666B2 (en) 2020-12-29
ES2738448T3 (es) 2020-01-22
JP2015509964A (ja) 2015-04-02
RU2636234C2 (ru) 2017-11-21
US9421202B2 (en) 2016-08-23
US20210290616A1 (en) 2021-09-23
CA2866020A1 (en) 2013-09-12
US20170042886A1 (en) 2017-02-16
KR20140143771A (ko) 2014-12-17
MX359209B (es) 2018-09-19
CN104540501B (zh) 2016-11-23
EP2822546B1 (en) 2017-07-12
US12433885B2 (en) 2025-10-07
EP2822546A1 (en) 2015-01-14
RU2014139955A (ru) 2016-04-27
JP6222608B2 (ja) 2017-11-01
HK1204985A1 (en) 2015-12-11
WO2013134398A1 (en) 2013-09-12
US20190099419A1 (en) 2019-04-04
ES2646008T3 (es) 2017-12-11
CA2866020C (en) 2020-09-22
US20240082241A1 (en) 2024-03-14
BR112014022123B1 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
HUE046667T2 (hu) Rák kombinatív kezelése
BR112014007603A2 (pt) métodos de tratamento do câncer
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
EP2819629A4 (en) PATIENT SUPPORT
HUE046790T2 (hu) A rák kezelésének módszerei
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
BR112014032105A2 (pt) método para o tratamento de câncer
BR112014012880A2 (pt) tratamento imunogênico do câncer
EP2832398A4 (en) MEDICAL SHUTTER
DK2914261T3 (da) Syntetisk letalitet og behandling af cancer
DK3089749T3 (da) Kombinerede præparater til behandling af cancer
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
LT3563837T (lt) Terapija bakteriofagu
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3053578T3 (da) Kombinationscancerterapi ved hjælp af azabicycloforbindelse
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft